Immunic Previews Relapsing MS Data Ahead of Phase 3 Readout…

Event summary

Immunic to host virtual R&D day on September 9, 2026, ahead of Phase 3 ENSURE trial data readout for vidofludimus calcium in relapsing MS
Top-line data from Phase 3 trials expected by year-end 2026
Key opinion leaders from University of Pennsylvania and Mount Sinai Hospital to provide expert perspectives
Vidofludimus calcium combines Nurr1 activation and DHODH inhibition for dual neuroprotective and anti-inflammatory effects
Company also developing progressive MS program, with Phase 3 initiation expected later in 2026

The big picture

Immunic's upcoming data readout comes at a critical juncture for the relapsing MS market, where demand for oral therapies with both anti-inflammatory and neuroprotective properties is growing. The company's approach aims to address persistent unmet needs in a space currently dominated by treatments focused primarily on inflammation control. Success with vidofludimus calcium could reshape treatment paradigms and position Immunic as a key player in neurologic disease therapeutics.

What we're watching

Clinical Efficacy: Whether vidofludimus calcium's differentiated mechanism can demonstrate superior outcomes in relapsing MS patients compared to existing therapies
Regulatory Pathway: The pace at which Immunic can advance vidofludimus calcium through regulatory approvals if Phase 3 data is positive
Pipeline Expansion: How successful progression into progressive MS trials could position Immunic as a leader in MS treatment